EIDP, Inc. · CTA-PA · FY2025 Q2 · Calendar Q3 2025
Corteva Raises 2025 Outlook After Strong First Half
The supplied analysis presents a raised full-year outlook supported by first-half growth, seed share gains, out-licensing and cost savings. Whether that outlook is sustained depends in part on execution amid crop-protection pricing pressure, currency headwinds and seasonal cash-flow needs.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
unavailableAsk FN2 about CTA-PA FY2025 Q2
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Management raised its full-year 2025 operating EBITDA guidance to $3.75–$3.85 billion and free-cash-flow guidance to approximately $1.9 billion, citing first-half performance. The analysis also reports that cost-improvement execution was on track and seed and out-licensing momentum continued.
Guidance delta
Raised: full-year 2025 operating EBITDA guidance to $3.75–$3.85 billion and free cash flow to approximately $1.9 billion. The supplied analysis says first-half results prompted a $100 million increase to the EBITDA midpoint.
Key takeaways
- The first half delivered double-digit EBITDA growth and roughly 300 basis points of margin expansion, according to the supplied analysis.
- Seed share gains and out-licensing were cited as growth drivers; Crop Protection grew volume despite pricing pressure in Brazil.
- Management said the 2025 cost-improvement target was on track, with more than $400 million of productivity savings delivered.
- The analysis cites new Crop Protection launches and biologicals expansion as execution priorities.
- Management reaffirmed a dividend increase and a $1 billion share-repurchase program.
Management priorities
- Build seed-market momentum through proprietary genetics and trait offerings.
- Expand out-licensing and progress toward royalty neutrality.
- Roll out Haviza and Reklemel and expand the biologicals portfolio.
- Continue cost-productivity efforts toward the stated 2027 target.
- Execute the announced dividend increase and share-repurchase program.
Follow CTA-PA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationEIDP, Inc. is an agricultural enterprise focused on creating and providing commercial seed and crop protection products. Its operations span across a wide global area, encompassing the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. The company's business is structured into two main divisions: Seed and Crop Protection. Through its Seed segment, EIDP, Inc. offers a variety of products including corn, soybean, and other oil seeds. This division also develops innovative trait technologies that enhance crops' natural defenses against challenging weather, diseases, insects, and herbicides used for weed control.…
Historical context
All CTA-PA earningsBasic Materials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| SQM Sociedad Química y Minera de Chile S.A. | FY2026 Q3 · Calendar Q4 2026 | -3.0% | -5.5% | SQM Sees Lithium Demand Growth but Flags Price and Inventory Risks |
| CTA-PB EIDP, Inc. USD 4.50 Cum Pfd Registered Shs | FY2026 Q3 · Calendar Q3 2026 | — | — | New-product growth held up, but Brazil weakness cut the EBITDA outlook |
| VYLR Vylor Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.1% | -0.1% | Vylor reaffirms 2026 outlook as Brazil licensing model shifts |
| CTVA Corteva, Inc. | FY2026 Q3 · Calendar Q4 2026 | +231.9% | -19.6% | Corteva Q3: New Products Grow as Brazil Weakness Cuts Outlook |
| FNV Franco-Nevada Corporation | FY2026 Q3 · Calendar Q4 2026 | +6.8% | -2.4% | Franco-Nevada Q3: stronger earnings, but revenue missed estimates |
Latest beats and misses
Who reports nextBeat on EPS
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
- WMGFY2026 Q4 · November 19, 2026+50.9% EPS-0.6% move
Missed on EPS
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
- XPFY2026 Q3 · November 16, 2026-3.0% EPS-2.5% move
Get the CTA-PA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-13. For educational purposes only; not investment advice.